CagriSema vs Survodutide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CagriSema
CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study.
Full profileSurvodutide
Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma. It pairs GLP-1's appetite suppression with glucagon-driven energy expenditure and hepatic fat oxidation — a mechanism especially promising for fatty-liver disease. It is not FDA-approved.
Full profile| CagriSema | Survodutide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Cagrilintide + Semaglutide, AM833 + semaglutide, amylin/GLP-1 combination | BI 456906, Glucagon/GLP-1 dual agonist, Zealand/Boehringer dual agonist |
| Evidence | Investigational (in trials) | Investigational (in trials) |
| Dosing range | 0.25mg–2.4mg mg, once weekly subcutaneous (each component 2.4mg at target) | 0.3mg–6mg mg, once weekly subcutaneous |
| Administration | Subcutaneous injection (weekly) | Subcutaneous injection (weekly) |
| Key side effects | Nausea (most common, dose-dependent), Vomiting, Diarrhea or constipation, Decreased appetite | Nausea (dose-dependent, during titration), Vomiting, Diarrhea, Decreased appetite |
| Cited sources | 2 references | 2 references |
Key differences
- Frequency: CagriSema is typically once weekly subcutaneous (each component 2.4mg at target); Survodutide is once weekly subcutaneous.
How each works
CagriSema
CagriSema combines amylin-receptor agonism (cagrilintide — satiety and gastric emptying via the area postrema/hypothalamus) with GLP-1 agonism (semaglutide), two non-overlapping appetite mechanisms. The REDEFINE 1 and 2 trials supported a December 2025 FDA filing for weight management. However, the open-label REDEFINE-4 head-to-head trial showed 23.0% weight loss vs 25.5% for tirzepatide 15 mg, missing its primary non-inferiority endpoint. An FDA decision is expected in late 2026.
Survodutide
Survodutide activates both the glucagon receptor (increasing energy expenditure and liver fat oxidation) and the GLP-1 receptor (reducing appetite and slowing gastric emptying). Its Phase 3 SYNCHRONIZE-1 obesity trial met its primary endpoint with meaningful weight loss at 76 weeks, and survodutide holds FDA Breakthrough Therapy designation for non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis. As of mid-2026 it remains investigational, with efficacy figures at the topline/conference stage.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.